1. "Sujata Patil"
  2. "Elizabeth Comen"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (6)
Groups
  1. Biostatistics Service (25)
  2. Breast Medicine Service (25)
  3. Department of Medicine (25)
  4. Epidemiology and Biostatistics (25)
  5. Solid Tumor Oncology Division (25)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (24)

More Groups

People
  1. Elizabeth Comen (25)
  2. Sujata Patil (25)
  3. Larry Norton (21)
  4. Clifford Hudis (16)
  5. Shanu Modi (11)
  6. Stephen Solomon (11)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2020 (3)
  5. 2019 (4)
  6. 2016 (3)

More Years

Publications
  1. Cancer Research (9)
  2. Journal of Clinical Oncology (8)
  3. Annals of Oncology (1)
  4. Breast Cancer Research and Treatment (1)
  5. Clinical Breast Cancer (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (10)
  2. American Society of Clinical Oncology (9)
  3. Biomed Central Ltd (1)
  4. Cell Press (1)
  5. Elsevier Inc. (1)
  6. Nature Research (1)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer
    Journal Article

    Comen, E.; Budhu, S.; Elhanati, Y.; Page, D.; Rasalan-Ho, T.; Ritter, E.; Wong, P.; Plitas, G.; Patil, S.; Brogi, E.; more...
    iScience (2024)

    Fulltext@MSK | Save
  • A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; McAndrew, P.; Larkin, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; Park, D. J.; McAndrew, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
    Meeting Abstract

    McArthur, H.; Comen, E.; Bryce, Y.; Solomon, S. B.; Leal, J.; Rodine, M.; Abaya, C. D.; Patil, S.; Page, D.; Norton, L.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Rodine, M.; Abaya, C. D.; Patil, S.; Page, D. B.; Norton, L.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC)
    Meeting Abstract

    Comen, E. A.; Bryce, Y.; Page, D. B.; Solomon, S. B.; Rodine, M.; Abaya, C. D.; Morris, E. A.; Plitas, G.; El-Tamer, M.; Gemignani, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Solomon, S.; Rodine, M.; DiLauro Abaya, C.; Leal, J. H. S.; Patil, S.; Norton, L.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save